Difference between revisions of "Termination control"

From apm
Jump to: navigation, search
m (de-novo proteins: capitalization)
(Related: added backlink to Incremental path)
Line 42: Line 42:
 
== Related ==
 
== Related ==
  
 +
* [[Incremental path]]
 
* [[Self assembly]]
 
* [[Self assembly]]
 
* [[Algorithmic selfassembly]]
 
* [[Algorithmic selfassembly]]

Revision as of 11:09, 5 August 2022

This article defines a novel term (that is hopefully sensibly chosen). The term is introduced to make a concept more concrete and understand its interrelationship with other topics related to atomically precise manufacturing. For details go to the page: Neologism.

Examples of termination control:
– rotationally symmetric assembly with specifiable number of segments left out
– in self-assemlbly terminating grid of voxels (carterian, hexagonal, or whatever) where
subsets of those voxels (ideally each one individually) can be set or unset (addressed) individually.

Using the terminology of "addressing voxels" may be confusing:
There are no changes after assembly. Static structural structures are assumed here.

Delineation from superficially impressive firatures like size and symmetry:
Infinite symmetries like a non-terminating rod, plane, or volume are considered to possess zero termination control.
Note that this also holds for full 360° rotational symmetry despite there actually being termination.
Full circle termination is considered to be not a controlled one.
Full circle termination is rather considered to be accidental by the fact that ends happen to meet up.

Limiting factors in termination control and countermeasures

De-novo proteins

  • Artificial de-novo proteins can only provide a small set of orthogonal interfaces.
    And it is hard to get high specificity and activity at the same time
  • Their otherwise desired stiffness gets in the way.
    There is no DNA like step by step unzipping process possible.
    All bond breaking energy needs to be supplied in one fell swoop.
    That is: Kinetic traps can become a bigger problem.
  • Internal cohesion, external intefaces and eventual other external functionality are
    three mutually competing factors on the choice of side-chain sequences.
    Such a situation is not present in structural DNA nanotechnology.

Countermeasures:

Structural DNA nanotechnology

  • Diffusuion time.
    Especially for larger 3D structures exclusively made from short strands (oglionucleotide staple strands) the achievable yields drop down far.

Countermeasures:

  • Inclusion of longer strands (backbone scaffold strands) can increase effective concentration and
    thereby speed up selfassembly considerably. This comes with tradeoffs though. (wiki-TODO: refresh on that one)
  • Hierarchical self-assembly aka convergent self-assembly
  • Maybe tether-based / hinged-based assembly approaches?

Spiroligomers

  • Their otherwise desires stiffness gets in the way of self assembly and termination control.
    Due to them being less conforming they are less and tolerant to variations in complementary surface shapes. Also they are small-ish limiting the amount of encodable shape.
  • They are still quite small molecules which limits their reachion-site-choosing-specificity. Similar to the site specificity limitation problem in conventional chemistry.

Countermeasures:

  • Integrate into more termination-control-scalable background framework like e.g. as artificial side-chains in de-novo proteins.

Related

(TODO: look into formally quantifying the quantity of termination control)